HI
GALT icon

Harbour Investments’s Galectin Therapeutics GALT Stock Holding History

Harbour Investments’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-150
Closed -$624 – 4712
2025
Q4 		$624 Buy
+150
New +$790 ﹤0.01% 3520
2021
Q4 		– Sell
-284
Closed -$1K – 3026
2021
Q3 		$1K Hold
284
– – ﹤0.01% 3502
2021
Q2 		$1K Hold
284
– – ﹤0.01% 3555
2021
Q1 		$1K Buy
+284
New +$636 ﹤0.01% 3381

Other funds holding GALT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Harbour Investments's GALT Position: Q1 2026 in Review

Harbour Investments sold out of Galectin Therapeutics (GALT) in Q1 2026, closing a stake of 150 shares — an estimated $624 sold.

Harbour Investments first reported a position in GALT in Q1 2021 and held it in 4 quarters. The position peaked at $1K in Q3 2021. 98 funds tracked by Wall St. Rank hold GALT as of Q1 2026.

  • Harbour Investments reported no remaining Galectin Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Harbour Investments sold 150 Galectin Therapeutics shares in Q1 2026, an estimated $624.
  • Harbour Investments first reported a position in Galectin Therapeutics in Q1 2021 and held it in 4 quarters.
  • Harbour Investments's Galectin Therapeutics position peaked at $1K in Q3 2021.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2026.

Based on Harbour Investments's 13F filing for Q1 2026, filed 15 May 2026.